

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABGENIX.073AAPPLICATION NO.
10/727,155INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Babcock, et al.FILING DATE
December 2, 2003GROUP
1844

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>il</i>	1	5,436,154	7/95	Barbanti et al.	 	 	
<i>il</i>	2	6,090,382	7/00	Salfeld et al.	 	 	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)


<i>il</i>	3	Feldman, M. <u>Development of Anti-TNF Therapy for Rheumatoid Arthritis</u> <i>Nature Publishing Group</i> , 2(5):364-371 (2002).
	4	Michie, et al. <u>Tumour Necrosis Factor and Bacterial Sepsis</u> <i>British Journal Surgery</i> 76:670-671 (1989)
	5	Liang, et al. <u>Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin</u> <i>Biochemical and Biophysical Research Communications</i> 137(2):847-854 (1986)
	6	Meager, et al. <u>Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)</u> <i>Hybridoma</i> 6(3):305-311 (1987)
	7	Fendly, et al. <u>Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor</u> <i>Hybridoma</i> 6(4):359-370 (1987)
	8	Hirai, et al. <u>Production and Characterization of Monoclonal Antibodies to Human Tumor Necrosis Factor</u> <i>Journal of Immunological Methods</i> 96:57-62 (1987)
	9	Möeller, et al. <u>Monoclonal Antibodies to Human Tumor Necrosis Factor α: In Vitor and In Vivo Appliation</u> <i>Cytokine</i> 2(3):162-169 (1990)
	10	Bringman, et al. <u>Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta Application for Affinity Purification, Immunoassays, and as Structural Probes</u> <i>Hybridoma</i> 6(5):489-507 (1987)
<i>il</i>	11	Beutler, et al. <u>Passive Immuniation Against Cachectin/Tumor Necrosis Factor Protects Mice From Lethal Effect of Endotoxin</u> <i>Science</i> 30:869-871 (1985)

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT SEVERAL SHEETS IF NECESSARY	ATTY. DOCKET NO. ABGENIX.073A	APPLICATION NO. 10/727,155
	APPLICANT Babcock, et al.	
	FILING DATE December 2, 2003	GROUP 1644



EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
<i>R</i>	12 Tracey, et al. <u>Anti-Cachectin/TNF Monoclonal Antibodies Prevent Septic Shock During Lethal Bacteraemia</u> <i>Nature</i> 330:662-664 (1987)
	13 Mathison, et al. <u>Participation of Tumor Necrosis Factor in the Mediation of Gram Negative Bacterial Lipopolysaccharide-Induced Injury in Rabbits</u> <i>Journal of Clinical Investigation</i> 81:1925-1937 (1988)
	14 Shimamoto, et al. <u>Monoclonal Antibodies Against Human Recombinant Tumor Necrosis Factor: Prevention of Endotoxic Shock</u> <i>Immunology Letters</i> 17:311-318 (1988)
	15 Opal et al. <u>Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats From Lethal Infection with Pseudomonas Aeruginosa</u> <i>The Journal of Infectious Diseases</i> 161:1148-1152 (1990)
	16 Silva, et al. <u>Monoclonal Antibody to Endotoxin Core Protects Mice from Escherichia Coli Sepsis by a Mechanism Independent of Tumor Necrosis Factor and Interleukin-6</u> <i>The Journal of Infectious Diseases</i> 162:454-459 (1990)
	17 Hinshaw, et al. <u>Survival of Primates in LD100 Septic Shock Following Therapy With Antibody to Tumor Necrosis Factor (TNF)</u> <i>Circulatory Shock</i> 30:279-292 (1990)
	18 Kumar, et al. <u>Universal T Helper Cell Determinants Enhance Immunogenicity of a Plasmodium Falciparum Merozoite Surface Antigen Peptide</u> <i>The Journal of Immunology</i> 148(5):1499-1505 (1992)
	19 Babcock, et al. <u>A Novel Strategy for Generating Monoclonal Antibodies From single, Isolated Lymphocytes Producing Antibodies of Defined Specificities</u> <i>Proceedings of the National Academy of Sciences</i> 93:7843-7848 (1996)
	20 Jones, et al. <u>Crystal Structure of TNF</u> <i>Tumor Necrosis Factors: Structure, Function, and Mechanism of Action</i> 5:93-127 (1992)
	21 Lehmann, et al. <u>Lethal Toxicity of Lipopolysaccharide and Tumor Necrosis Factor in Normal and D-Galactosamine-Treated Mice</u> <i>Journal of Experimental Medicine</i> 165:657-663 (1987)
	22 Leist, et al. <u>Tumor Necrosis Factor-Induced Hepatocyte Apoptosis Precedes Liver Failure in Experimental Murine Shock Models</u> <i>American Journal of Pathology</i> 146(5):1220-1234 (1995)
	23 Nowak, et al. <u>LPS-Induced Liver Injury in D-Galactosamine-Sensitized Mice Required Secreted TNF-α and the TNF-p55 Receptor</u> <i>American Journal of Physiological Society</i> 278:R1202-R1209 (2000)
	24 Benigni, et al. <u>TNF Receptor p55 Plays a Major Role in Centrally Mediated Increases of Serum IL-6 and Corticosterone After Intracerebroventricular Injection of TNF1</u> <i>The American Association of Immunologists</i> 0022-1767:5563-5568 (1996)
	25 Chothia, et al. <u>Canonical Structures for the Hypervariable Regions of Immunoglobulins</u> <i>Journal of Molecular Biology</i> 96:901-917 (1987)
	26 Chothia, et al. <u>Conformations of Immunoglobulin Hypervariable Regions</u> <i>Nature Publishing Group</i> 342:877-883 (1989)
	27 Martin, et al. <u>Structural Families in Loops of Homologous Proteins: Automatic Classification, Modelling and Application to Antibodies</u> <i>Journal Molecular Biology</i> 263:800-815 (1996)
	28 Ostade, et al. <u>Human TNF Mutants With Selective Activity on the p55 Receptor</u> <i>Nature</i> 361:266-269 (1993)
<i>R</i>	29 Ostade, et al. <u>Localization of the Active Site of Human Tumor Necrosis Factor (hTNF) by Mutational Analysis</u> <i>The EMBO Journal</i> 10(4):827-836 (1991)

S:\DOCS\WCB\WCB-2978.DOC
082704

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>12/1/05</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	



PTO/SB/08 Equivalent

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/727,155
Filing Date	December 2, 2003
First Named Inventor	John S. Babcock
Art Unit	1644
Examiner	Unassigned
Attorney Docket No.	ABGENIX.073A

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
R	1	Hochberg et al., 2003, <i>Ann. Rheum. Dis.</i> , Vol. 62 (Suppl. II):ii13-ii16.	

1349351_1
031705

Examiner Signature

Date Considered

12/1/05

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.